Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Slides:

Advertisements

Similar presentations

Richardson PG et al. Proc ASH 2013;Abstract 535.

Advertisements

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Multiple Myeloma Plasma cell disorder: CRAB Estimated 24,050 cases and 11,090 deaths in 2014 [1] Median age at diagnosis: 69 yrs [2] 5-yr survival has.

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.

Multiple Myeloma: Is it now a curable disease?

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.

Myeloma hope new treatment in the horizon

Upfront Combination Therapy vs Step-Up Approach for PAH:

The Patient Experience With Systemic Lupus Erythematosus

The Nurse View.

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Diabetic Dyslipidemia in Practice

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Challenging Cases in Multiple Myeloma Panel Discussion

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

The HCV Revolution: Are You and Your Practice Ready?

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( ) Sundar Jagannath, Rafat Abonour, Brian.

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Selecting MM Therapy in Patients With Comorbidities

nAMD: Switching Therapies - what you need to know

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Managing IBD in Children

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Tailoring Hemophilia Prophylaxis Therapy

The Nurse View: Best Practices in Multiple Myeloma

Checkpoint Inhibition

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Personalized Therapy in Relapsed or Refractory CLL

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

Staying Abreast of Best Practices Across the Clinical Continuum

New Classes of Therapy in Multiple Myeloma

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

A Guideline-Based Approach to HCV Care

Management of Advanced Pancreatic Adenocarcinoma

The Role of Maintenance Therapy in Multiple Myeloma

Response to Carfilzomib Therapy

Proteasome Inhibitors and Patients

On the Cusp: New Approaches for Multiple Myeloma

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Renal Function and Myeloma Therapeutics

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Spotlight on Monoclonal Antibodies in Multiple Myeloma

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Pulmonary Arterial Hypertension and Hospitalizations

What's New in PAH?.

Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Program Goals

Defining Multiple Myeloma

Case 1

Diagnostic Criteria Multiple Myeloma Requiring Therapy

Cytogenetic Risk Features

Case 1 (cont)

Newly Diagnosed Multiple Myeloma NCCN® Therapy for Transplant-Eligible Patients

FIRST Trial

SWOG S0777 Trial

Therapy Modifications With PN

Peripheral Neuropathy in Multiple Myeloma

Nursing Care for Peripheral Neuropathy

Nursing Care for Peripheral Neuropathy (cont)

Therapy Classes for MM

Bisphosphonates in MM IMWG Recommendations

Maintenance Therapy

Patient Case 1 (cont)

Multiple Myeloma Therapy for Previously Treated Disease

Shared Decision Making

Considerations for This Patient

Ixazomib/Lenalidomide/ Dexamethasone Therapy

Strategies to Aid Patient Compliance

ELOQUENT-2 Len/Dex ± Elotuzumab

Elotuzumab

Therapy and Diagnostic Testing

Carfilzomib: Clinical Trials

Carfilzomib

Patient Case 1 Combinations With Len/Dex at Early Relapse

Daratumumab Anti-CD38 Antibody

Daratumumab

Managing Infections

Pomalidomide

Panobinostat

Survivorship Plans

Survivorship Plans (cont)

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)